Mardozia (Dorzolamide, Timolol)

Mardozia is used in the management of ocular conditions that involve elevated intra‑ocular pressure.

• Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage and preserve visual field.
• Ocular hypertension: lowers eye pressure to prevent progression to glaucoma.
• Post‑surgical ocular pressure control: helps maintain target pressure after ocular procedures.

• Dorzolamide inhibits carbonic anhydrase in the ciliary body, decreasing aqueous humor formation, while timolol blocks β‑adrenergic receptors on ocular tissues, reducing aqueous humor secretion. The combined effect results in a significant reduction of intra‑ocular pressure, addressing the primary pathogenic factor in glaucoma and ocular hypertension. By targeting two distinct pathways, the formulation provides additive pressure‑lowering efficacy with a rapid onset of action after topical administration.

The most frequently reported ocular and systemic reactions to Mardozia are listed below.

Common Side Effects

• Eye irritation or burning sensation
• Temporary blurred vision
• Bitter taste after instillation
• Eye redness
• Headache

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angioedema, anaphylaxis)
• Significant bradycardia or heart block
• Bronchospasm in susceptible individuals
• Persistent corneal ulceration

Before prescribing Mardozia, clinicians should consider the following precautions.

• Assess baseline intra‑ocular pressure: ensure appropriate target pressure is set.
• Monitor for systemic beta‑blocker effects: watch for bradycardia, hypotension, or bronchospasm.
• Evaluate sulfonamide allergy: dorzolamide contains a sulfonamide moiety.
• Use with caution in patients with severe asthma or chronic obstructive pulmonary disease.
• Store at room temperature: keep in the original container, protect from light and moisture.

Mardozia may interact with other medications; notable interactions are categorized below.

Major Interactions (Avoid)

• Concomitant non‑selective beta‑blockers: risk of additive bradycardia and hypotension.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): may cause excessive reduction of aqueous humor production.
• Sympathomimetic eye drops (e.g., epinephrine): can diminish the IOP‑lowering effect.

Moderate Interactions (Monitor Closely)

• Other ocular hypotensive agents (e.g., prostaglandin analogues): may require dose adjustment.
• Antihypertensive drugs (e.g., calcium channel blockers): monitor blood pressure and heart rate.
• Antidepressants affecting serotonergic pathways: observe for rare cardiac effects.